論文・総説 - 小早川　拓也

分割表示  72 件中 1 - 20 件目  ／  全件表示 >>

  1. Higashi-Kuwata N, Bulut H, Hayashi H, Tsuji K, Ogata-Aoki H, Kiso M, Takamune N, Kishimoto N, Hattori SI, Ishii T, Kobayakawa T, Nakano K, Shimizu Y, Das D, Saruwatari J, Hasegawa K, Murayama K, Sukenaga Y, Takamatsu Y, Yoshimura K, Aoki M, Furusawa Y, Okamura T, Yamayoshi S, Kawaoka Y, Misumi S, Tamamura H, Mitsuya H. An orally available P1'-5-fluorinated M(pro) inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier. PNAS nexus. 2025.01; 4 (1): pgae578. ( PubMed, DOI )

  2. Shinohara K, Kobayakawa T, Tsuji K, Takamatsu Y, Mitsuya H, Tamamura H. Naphthalen-1-ylethanamine-containing small molecule inhibitors of the papain-like protease of SARS-CoV-2. European journal of medicinal chemistry. 2024.12; 280 116963. ( PubMed, DOI )

  3. Kobayakawa T, Tsuji K, Tamamura H. Design, synthesis and evaluation of bioactivity of peptidomimetics based on chloroalkene dipeptide isosteres. Bioorganic & medicinal chemistry. 2024.08; 110 117811.

  4. Kobayakawa, T; Azuma, C; Yamamoto, K; Tsuji, K; Tamamura, H. | Convergent synthesis of peptidomimetic based on a chloroalkene dipeptide isostere and its application to inhibition against amyloid ß aggregation JOURNAL OF PEPTIDE SCIENCE. 2024.08; 30

  5. Tamamura, H; Higashi-Kuwata, N; Mitsuya, H; Tsuji, K; Ishii, T; Kobayakawa, T. Prevention of the spread of virus infection in global societies: anti-SARS-CoV-2 agents learned from HIV researches JOURNAL OF PEPTIDE SCIENCE. 2024.08; 30

  6. Ishii T, Kobayakawa T, Matsuda K, Nigorikawa K, Bolah P, Noborio A, Tsuji K, Ohashi N, Yoshimura K, Nomura W, Mitsuya H, Maeda K, Tamamura H. Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents. ACS infectious diseases. 2024.05; 10 (6): 2250-2261. ( PubMed, DOI )

  7. Kobayakawa Takuya, Yokoyama Masaru, Tsuji Kohei, Boku Sayaka, Kurakami Masaki, Fujino Masayuki, Ishii Takahiro, Miura Yutaro, Nishimura Soshi, Shinohara Kouki, Yamamoto Kenichi, Bolah Peter, Kotani Osamu, Murakami Tsutomu, Sato Hironori, Tamamura Hirokazu. Development of Small-Molecule Anti-HIV-1 Agents Targeting HIV-1 Capsid Proteins(タイトル和訳中) Chemical & Pharmaceutical Bulletin. 2024.01; 72 (1): 41-47. ( 医中誌 )

  8. Kobayakawa T, Takano H, Ishii T, Bolah P, Tsuji K, Ohashi N, Nomura W, Furuta T, Tamamura H. Effect of Two-Photon Excitation to 8-Azacoumarin Derivatives as Photolabile Protecting Groups. Chemical & pharmaceutical bulletin. 2024; 72 (3): 311-312. ( PubMed, DOI )

  9. Kobayakawa T, Yokoyama M, Tsuji K, Boku S, Kurakami M, Fujino M, Ishii T, Miura Y, Nishimura S, Shinohara K, Yamamoto K, Bolah P, Kotani O, Murakami T, Sato H, Tamamura H. Development of Small-Molecule Anti-HIV-1 Agents Targeting HIV-1 Capsid Proteins. Chemical & pharmaceutical bulletin. 2024; 72 (1): 41-47. ( PubMed, DOI )

  10. Tsuji Kohei, Kobayakawa Takuya, Ishii Takahiro, Higashi-Kuwata Nobuyo, Azuma Chika, Shinohara Kouki, Miura Yutaro, Yamamoto Kenichi, Nishimura Soshi, Hattori Shin-ichiro, Bulut Haydar, Mitsuya Hiroaki, Tamamura Hirokazu. Exploratory Studies of Effective Inhibitors against the SARS-CoV-2 Main Protease by Halogen Incorporation and Amide Bond Replacement(タイトル和訳中) Chemical & Pharmaceutical Bulletin. 2023.12; 71 (12): 879-886. ( 医中誌 )

  11. Tsuji K, Ishii T, Kobayakawa T, Higashi-Kuwata N, Shinohara K, Azuma C, Miura Y, Nakano H, Wada N, Hattori SI, Bulut H, Mitsuya H, Tamamura H. Structure-Activity Relationship Studies of SARS-CoV-2 Main Protease Inhibitors Containing 4-Fluorobenzothiazole-2-carbonyl Moieties. Journal of medicinal chemistry. 2023.09; 66 (19): 13516-13529. ( PubMed, DOI )

  12. Ishii T, Kobayakawa T, Matsuda K, Tsuji K, Ohashi N, Nakahata S, Noborio A, Yoshimura K, Mitsuya H, Maeda K, Tamamura H. Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity. European journal of medicinal chemistry. 2023.08; 256 115449. ( PubMed, DOI )

  13. Kohei Tsuji, Kofi Baffour-Awuah Owusu, Yutaro Miura, Takahiro Ishii, Kouki Shinohara, Takuya Kobayakawa, Akino Emi, Takashi Nakano, Youichi Suzuki, Hirokazu Tamamura . Dimerized fusion inhibitor peptides targeting the HR1–HR2 interaction of SARS-CoV-2 RSC Advances. 2023.03; 13 8779-8793.

  14. Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, Takamune N, Kishimoto N, Hattori SI, Das D, Uemura Y, Shimizu Y, Aoki M, Hasegawa K, Suzuki S, Nishiyama A, Saruwatari J, Shimizu Y, Sukenaga Y, Takamatsu Y, Tsuchiya K, Maeda K, Yoshimura K, Iida S, Ozono S, Suzuki T, Okamura T, Misumi S, Kawaoka Y, Tamamura H, Mitsuya H. Identification of SARS-CoV-2 M(pro) inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nature communications. 2023.02; 14 (1): 1076. ( PubMed, DOI )

  15. Tsuji K, Kobayakawa T, Ishii T, Higashi-Kuwata N, Azuma C, Shinohara K, Miura Y, Yamamoto K, Nishimura S, Hattori SI, Bulut H, Mitsuya H, Tamamura H. Exploratory Studies of Effective Inhibitors against the SARS-CoV-2 Main Protease by Halogen Incorporation and Amide Bond Replacement. Chemical & pharmaceutical bulletin. 2023; 71 (12): 879-886. ( PubMed, DOI )

  16. Matsuura K, Yamaura M, Sakawaki H, Himeno A, Pisil Y, Kobayakawa T, Tsuji K, Tamamura H, Matsushita S, Miura T. Sensitivity to a CD4 mimic of a consensus clone of monkey-adapted CCR5-tropic SHIV-MK38C. Virology. 2022.12; 578 171-179. ( PubMed, DOI )

  17. Kitamura H, Sukegawa S, Matsuda K, Tanimoto K, Kobayakawa T, Takahashi K, Tamamura H, Tsuchiya K, Gatanaga H, Maeda K, Takeuchi H. 4-phenylquinoline-8-amine induces HIV-1 reactivation and apoptosis in latently HIV-1 infected cells. Biochemical and biophysical research communications. 2022.12; 641 139-147. ( PubMed, DOI )

  18. Matsumoto K, Kuwata T, Tolbert WD, Richard J, Ding S, Prévost J, Takahama S, Judicate GP, Ueno T, Nakata H, Kobayakawa T, Tsuji K, Tamamura H, Smith AB 3rd, Pazgier M, Finzi A, Matsushita S. Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates. Journal of virology. 2022.12; 97 (1): e0163822. ( PubMed, DOI )

  19. Tsuji K, Ishii T, Kobayakawa T, Higashi-Kuwata N, Azuma C, Nakayama M, Onishi T, Nakano H, Wada N, Hori M, Shinohara K, Miura Y, Kawada T, Hayashi H, Hattori SI, Bulut H, Das D, Takamune N, Kishimoto N, Saruwatari J, Okamura T, Nakano K, Misumi S, Mitsuya H, Tamamura H. Potent and biostable inhibitors of the main protease of SARS-CoV-2. iScience. 2022.11; 105365. ( PubMed, DOI )

  20. Tsuji K, Ishii T, Kobayakawa T, Higashi-Kuwata N, Azuma C, Nakayama M, Onishi T, Nakano H, Wada N, Hori M, Shinohara K, Miura Y, Kawada T, Hayashi H, Hattori SI, Bulut H, Das D, Takamune N, Kishimoto N, Saruwatari J, Okamura T, Nakano K, Misumi S, Mitsuya H, Tamamura H. Potent and biostable inhibitors of the main protease of SARS-CoV-2. iScience. 2022.11; 105365. ( PubMed, DOI )

< 前のページ - 次のページ >

このページの先頭へ▲